KEY TAKEAWAY:Gilead, which recently acquired Kite Pharma in an all cash deal, said the list price for Yescarta, which is to be administered just once to each patient, would be $373,000. The cost is supposed to make us feel good because the price is well below that of the first drug in this new class such as $475,000 for Novartis’s Kymriah.
Fast Company found that women visit physicians more frequently and ask more questions after exams, especially expectant mothers. In addition, roughly[inlinetweet prefix=”” tweeter=”” suffix=””] 80 percent of healthcare decisions in households are made by women[/inlinetweet], and women are more likely to take care of family members when they get sick.
According to the Atlantic “opioid abuse is rampant in states like Ohio, where paramedics are increasingly spending time responding to overdoses and where coroners’ offices are running out of room to store bodies. In 2012, there were 793 million doses of opioids prescribed in the state, enough to supply every man, woman, and child, with 68 pills each”. But is pharma really to blame?
According to CNN.com “The United States will not be escaping the obesity epidemic crisis anytime soon: Nearly 40% of adults and 19% of youth are obese, the highest rate the country has ever seen in all adults, according to research released Friday by the National Center for Health Statistics”. So who is responsible for telling patients to lose weight?
One of the best experiences of my career was working at Eli Lilly. They gave me the tools to succeed in an environment that promoted thinking outside of the box. Today, the Lilly that I knew and loved is a shell of its former self driven down by a combination of loosing really good people and patent expirations.
KEY TAKEAWAY: Americans use the internet or mobile apps as their first source for information about specific health symptoms, conditions, diseases, or ailments. So comes this eye opening (cue sarcasm) from United Health Care.